What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Victoza (also known as Liraglutide) and Atorvastatin (VA) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene
From the Significance of the study to Public health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) out of 55 million deaths that occur every year, nearly 18.33 million deaths are due to cardiovascular causes; (3) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (4) 85% of people over 80 years are susceptible to cardiovascular diseases;(5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; and (8) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year from 2030 onwards, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free natural product-based drug.
From research findings to therapeutic opportunity:
This study suggests, for the first time, that a therapeutic mix encompassing Victoza and Atorvastatin (VA), by increasing the expression of its target gene, it may suppress the expression of tumor suppressor and the ageing marker INK4a/p16 (figure 1).
Thereby, it may: (1) inhibit cardiac senescence/ageing; (2) increase regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility.
Thus, by treating myocardial patients with VA, one may prevent cardiac ageing; and delay ageing-associated (or, stress-associated) decline in cardiac function.
Taken together, pharmacological formulations encompassing “Victoza and Atorvastatin (VA) or their analogs, either alone or in combination with other drugs“ may be used to inhibit cardiac senescence, cardiac ageing and myocardial infarction (figure 1).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How a therapeutic mix encompassing Victoza and Atorvastatin (VA) suppresses the expression of tumor suppressor INK4a/p16.
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
Web: http://genomediscovery.org or newbioideas.com
Citation: Boominathan, L., Cardiac rejuvenation therapy: A therapeutic mix encompassing Victoza and Atorvastatin (VA) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene, 13/November/2017, 11.35 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org